Background: HepaCAM (Hepatocyte cell adhesion molecule), also known as GlialCAM, is a 416 amino acid single-pass type I membrane protein that contains one Ig-like C2-type domain and one Ig-like V-type domain. Localized to the cytoplasmic side of the membrane, HepaCAM exists as a homodimer that is involved in regulating both cell-matrix interactions and cell motility. Additionally, HepaCAM is thought to suppress cellular proliferation, suggesting involvement in cell growth inhibition and tumor suppression, specifically with regard to hepatocellular carcinoma. Deletion of the cytoplasmic domain of HepaCAM results in diminished cell-matrix adhesion, implying that the cytoplasmic domain is a crucial component of HepaCAM function. Two isoforms of HepaCAM exist due to alternative splicing events.
Description: Rabbit polyclonal to HepaCAM
Immunogen: KLH conjugated synthetic peptide derived from HepaCAM
Specificity: ·Reacts with Human, Mouse, Pig, Dog, Rabbit and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 46 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-200;
·Immunocytochemistry: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
